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Primary prevention and early detection of cardiovascular disease is important, as it 
is the leading cause of death throughout world. Risk stratification algorithms, such 
as Framingham Risk Score and European Systematic Coronary Risk Evaluation, 
that utilize a combination of various traditional risk factors have been developed to 
improve primary prevention. However, the accuracy of these algorithms for screen-
ing high risk patients is moderate at best. Accordingly, the use of biomarkers or im-
aging studies may improve risk stratification. Carotid ultrasound, which measures 
both carotid intima-media thichkness (cIMT) and carotid plaque, is useful in detect-
ing the degree of subclinical carotid atherosclerosis, and has the advantage of being 
noninvasive and safe. Several large epidemiologic studies have indicated that cIMT 
and carotid plaque are closely related with other cardiovascular risk factors and 
may be useful for risk reclassification in subjects deemed to be at intermediate risk 
by traditional risk scores. Moreover, recent clinical guidelines for management of 
hypertension or dyslipidemia highlight the usefulness of cIMT in high risk patients. 
In this article, we review evidence for the usefulness of measurement of cIMT and 
carotid plaque for cardiovascular risk stratification.
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INTRODUCTION
 
Cardiovascular disease is the leading cause of mortality throughout the world, with 
studies showing cardiovascular disease to be the cause of death in 30% of all mortali-
ties reported in the USA.1 Atherosclerosis is a disease process that begins at an early 
age and is progressive in nature. Atherosclerotic lesions do not arouse any symptoms 
in the early stage, but its initial presentation may result in catastrophic cardiovascular 
events resulting from plaque rupture.2 As such, it is imperative to identify subjects at 
increased risk of cardiovascular disease and modify their risk factors early on. Also, 
the treatment of advanced atherosclerosis is less effective than the inhibition of ath-
erosclerosis progression.3 However, traditional risk factors for predicting cardiovascu-
lar disease, such as the Framingham Risk Score (FRS) and the European Systematic 
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have revealed some limitations with the NCEP-ATPIII 
guidelines on risk stratification. Akosah, et al. showed that 
the only 25% of young patients with acute myocardial in-
farction would have been recommended for statin drug 
therapy criteria according to NCEP-ATPIII guidelines.11 In 
addition, this guideline did not categorize 69% of acute 
myocardial infarction patients to the drug therapy group in 
a large cohort without a history of coronary artery disease.12 
High blood pressure is one of the most important causes 
of cardiovascular disease and there is no argument that 
treatment of hypertension lowers cardiovascular risk. How-
ever, in the British United Provident Association (BUPA) 
study, which included 21520 subjects of ages 35-64 years, 
blood pressure was not a strong indicator for prediction of 
future cardiovascular events. The study demonstrated that 
the distribution of blood pressures among men who died of 
ischemic heart disease and men who did not exhibited no-
ticeable overlap.13 
Risk factors, like those above, are closely related with the 
incidence and the progression of atherosclerosis. However, 
these are indirect rather than direct markers for the current 
status of atherosclerosis and have limitations for evaluating 
atherosclerosis. Thus, more direct markers with anatomical 
delineation through imaging technology or functional stud-
ies have been developed and widely used. Among them, 
many researchers or clinicians have utilized cIMT measure-
ment via ultrasonography.
ADVANTAGES OF cIMT 
MEASUREMENT WITH CAROTID 
ULTRASOUND
Carotid ultrasonography can measure cIMT and detect fo-
cal atherosclerotic plaque using ultrasound. The measure-
ment of cIMT has several advantages for monitoring of ath-
erosclerosis. First, cIMT can be performed with no adverse 
effects on subjects. Second, cIMT can be carried out at rela-
tively low cost. Third, cIMT gives better visualization of ath-
erosclerotic changes on arterial wall than other imaging mo-
dalities. In addition, ultrasound B-mode imaging of cIMT 
has been shown to be well correlated with IMT measured 
on microscopic examination.14 Therefore, the measurement 
of cIMT can provide precise information about atheroscle-
rotic burden. Data from several sources have identified that 
traditional risk prediction models could not accurately re-
flect the presence of atherosclerosis as measured by carotid 
Coronary Risk Evaluation, comprise modest predictive value 
for future cardiovascular events.4 For this reason, the treat-
ment of atherosclerosis at an earlier stage is crucial with more 
precise patient selection for preventive treatment. Landmark 
studies have demonstrated that measurements of subclinical 
atherosclerosis, such as carotid ultrasound, ankle brachial in-
dex and coronary calcium score, offer significant benefit in 
improving cardiovascular risk prediction beyond that with 
traditional risk factors.5-7 Among these measurements, ultra-
sonographic measurement of carotid intima-media thickness 
(cIMT) and carotid plaque have been widely applied to detect 
early atherosclerotic lesions. This review aims to discuss up 
to date evidence for the clinical usefulness of cIMT and 
plaque measurement for cardiovascular risk stratification.  
LIMITATIONS OF TRADITIONAL RISK 
FACTORS FOR CARDIOVASCULAR  
RISK STRATIFICATION 
In spite of recent advances in treatment strategies, the inci-
dence of cardiovascular disease is expected to increase as a 
result of ageing populations.8 In addition, the socioeco-
nomic cost thereof is high due to the chronic nature of car-
diovascular disease. Therefore, the establishment of a pre-
vention plan is essential, and research regarding biomarkers, 
imaging studies, and risk classification models for predict-
ing cardiovascular events have been studied extensively.
Although FRS is the standard score system for predicting 
cardiovascular risk using traditional risk factors, it is mod-
est at best in predicting cardiovascular risk. This is not sur-
prising since studies have shown that the majority of pa-
tients with cardiovascular disease would have been classified 
as low risk by traditional risk scores. A 26-year follow-up 
data of the Framingham Heart Study revealed that 35% of 
subjects with total cholesterol level below 200 mg/dL, 
which is considered a desirable cholesterol level, were pre-
disposed to cardiovascular disease. Moreover, the total cho-
lesterol levels were the same in 80% of individuals who ex-
perienced myocardial infarction versus those who did not 
experience the event.9 The National Cholesterol Education 
Program Adult Treatment Panel III (NCEP-ATPIII) guide-
lines, which are based on FRS, suggest that the target goal 
of low density lipoprotein (LDL) cholesterol lowering, the 
primary target for reduction of cardiovascular disease, dif-
fers according to risk category, as determined using tradi-
tional cardiovascular risk factors.10 However, some studies 
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risk for cardiovascular disease was estimated using an algo-
rithm including total cholesterol, blood pressure, smoking, 
and diabetes mellitus (DM), individuals with higher life time 
risk experienced a greater subclinical atherosclerosis burden.22 
These associations between traditional risk factors for cardio-
vascular disease and cIMT suggest that cIMT exhibits poten-
tial as a surrogate marker for predicting cardiovascular events. 
Many prospective studies have evaluated the relationship 
between cIMT and cardiovascular clinical events.23 Although 
each study set a differing cutoff point of high risk, the stud-
ies demonstrated an absolute yearly risk for cardiovascular 
disease, ranging from 1.6% to 3.2%, with increase in cIMT. 
Additionally, the relative risk of high cIMT ranged from 2.2 
to 3.2 for coronary heart disease.24-26 The Atherosclerosis 
Risk In Communities (ARIC) study, which was an epide-
miologic study of cardiovascular incidence in the general 
population, revealed that a higher coronary heart disease in-
cidence was significantly associated with the both the in-
creasing degree of cIMT and the presence of plaque (Fig. 
1).27 Baldassarre, et al. demonstrated that the progression 
rate of maximum cIMT was significantly associated with 
cardiovascular risk.28 The results from the aforementioned 
epidemiologic studies clearly demonstrated that cIMT is as-
sociated with increased cardiovascular risk. 
IMPROVEMENT IN RISK 
STRATIFICATION USING A 
COMBINATION OF TRADITIONAL  
RISK FAVTORS AND cIMT 
　　　
Numerous studies have demonstrated that cIMT is a signifi-
cantly predictive for cardiovascular events. However, what 
ultrasonography. Naqvi, et al. studied the prevalence of 
subclinical atherosclerosis in the groups of low, intermedi-
ate, and high FRS in 136 asymptomatic subjects using ca-
rotid ultrasonography. In the 103 low-risk (FRS<10%) sub-
jects, 66% had cIMT>75th percentile or plaque >1.5 mm.15 
In another study, when carotid ultrasonography was per-
formed in 336 asymptomatic healthy young subjects with 
FRS of <5%, nearly 38% had high risk carotid ultrasound 
findings, defined as the cIMT>75th percentile. These stud-
ies demonstrated that traditional risk factors do not accu-
rately reflect the actual plaque burden in the arteries, and as 
such, cIMT may be of use for risk stratification.16 The re-
cently published European Society of Hypertension/Euro-
pean Society of Cardiology have defined either a mean 
cIMT of over 0.9 mm or the presence of carotid plaque as a 
marker of target organ damage in hypertension.17  
THE ASSOCIATION BETWEEN cIMT 
AND CARDIOVASCULAR RISK 
FACTORS
Studies have demonstrated significant correlations between 
the degree of cIMT with other cardiovascular risk factors. Age 
and high blood pressure are known to be major determinants 
of cIMT in the general population.18 This is consistent with 
the fact that atherosclerosis progresses with age and high 
blood pressure. Moreover, other proatherogenic factors, like 
total cholesterol, LDL-cholesterol and insulin resistance, have 
been shown to be significantly associated with cIMT.19,20 The 
Bougalusa Heart Study showed that the progression of cIMT 
was significantly associated with fasting blood glucose and 
systolic blood pressure in young adults.21 When the lifetime 
Fig. 1. The coronary heart disease incidence rate according to various carotid intima-media thickness (cIMT) categories with and without the presence of 
plaque. For the overall group (green bar), men (yellow bar), or women (orange bar), the higher cIMT and the presence of plaque is associated with a higher in-
cidence of coronary heart disease (Adapted from Nambi, et al. J Am Coll Cardiol 2010;55:1600-7, with permission from Elsevier).27
0
5
10
15
20
25
Co
ro
na
ry
 h
ea
rt 
di
se
as
e 
in
ci
de
nc
e 
ra
te
 p
er
 
10
00
 p
er
so
n 
ye
ar
s
cIMT<25th percentile, 
no plaque
cIMT<25th percentile, 
yes plaque
cIMT25-75 percentile, 
no plaque
cIMT25-75 percentile, 
yes plaque
cIMT>75 percentile, 
no plaque
cIMT>75 percentile, 
yes plaque
2.9
4.4
7.16.1
8.1
11.4
4.6
7.6
11.7
9
11
17
7.2
12.2
18.2
13.2
15.6
24.7
  Women
  Overall
  Men
Chan Joo Lee and Sungha Park
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014554
in 2965 subjects of the Framingham Offspring Study Co-
hort and found that the prediction of cardiovascular disease 
became better after addition of maximum intima-media 
thickness of internal carotid artery, with an improvement of 
the net reclassification index by 7.6% (p<0.001); however, 
no improvement in net reclassification was demonstrated 
when mean intima-media thickness of common carotid ar-
tery was added to the traditional risk factors. In this study, 
the presence of plaque, defined as internal cIMT of more 
than 1.5 mm, was associated with significant increase in 
both C statistics [0.014, 95% confidence interval (CI): 0.003-
0.025, p=0.02] and improvement in the net reclassification 
index by 7.3% (p<0.01). Also, the presence of plaque signif-
icantly improved the prediction of new-onset cardiovascular 
disease (Fig. 2). Therefore, the assessment of both common 
carotid and internal carotid plaque add incremental value in 
predicting cardiovascular events. 
Notwithstanding, cIMT may not be useful for risk strati-
is still not centain is the additional predictive value of  cIMT 
beyond traditional risk score. Lorenz, et al. studied the ad-
ditive value of cIMT using the 10-year follow-up data of 
4904 subjects from the Carotid Atherosclerosis Progression 
Study (CAPS).29 Subjects were reclassified to new risk stra-
ta using traditional risk prediction models with cIMT, and 
were compared to classifications based on traditional risk 
scores to determine the improvement in cardiovascular risk 
prediction with the addition of cIMT. Surprisingly, the risk 
prediction with cIMT did not demonstrate an improvement 
in cardiovascular risk prediction, compared to the tradition-
al risk prediction model. However, a study done in 13415 
subjects enrolled in the ARIC study showed that adding 
cIMT to traditional risk factors improves predictability. Also, 
this study showed that the addition of carotid plaque further 
improved the prediction strength.27 Likewise, Polak, et al. 
demonstrated that cIMT is able to contribute to improving 
traditional risk prediction models.5 They carried out a study 
Fig. 2. Kaplan-Meier estimates of new-onset cardiovascular disease (CVD) according to the presence of plaque. The 8-year rates of cardiovascular disease 
increase with the presence of internal carotid artery plaque for participants overall (A) and for each Framingham Risk Score category: low risk (0 to <6%) (B), 
intermediate risk (6 to 20%) (C), and high risk (>20%) (D) (Adapted from Polak, et al. N Engl J Med 2011;365:213-21, with permission from Massachusetts 
Medical Society).5
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be performed for the sole purpose of cardiovascular risk 
stratification.
LIMITATIONS OF cIMT AND ISSUES 
THAT NEED TO BE RESOLVED
Despite the widespread use of cIMT, it still has limitations. 
Above all, the threshold value of cIMT, above which the 
risk is increased, needs to be clearly defined. cIMT is af-
fected by multiple factors. Age is the most influential factor 
on cIMT and common cIMT increases 0.01 mm annually.33 
Thus, it is hard to apply one absolute value to the general 
population as abnormal IMT. Although the ESH/ESC guide-
lines define a high risk cIMT finding as a mean cIMT of 
more than 0.9 mm, this may not be generalizable to all pop-
ulations, especially Asians. In addition, as cIMT is a contin-
uous variable, a definition to distinguish between plaque 
and vessel wall hypertrophy is arbitrary. The 34th Bethesda 
conference suggested the use of nomograms or ratios of ob-
served to predicted IMT based on age and other factors af-
fecting cIMT, such as the approximate age-adjusted 75th 
percentile values for cIMT.34 The Manheim cIMT Consen-
sus defines plaque as a focal structure encroaching into the 
arterial lumen by at least 0.5 mm or 50% of the surround-
ing wall or demonstrates a plaque thickness of >1.5 mm.35 
However, each of these studies still used an arbitrary cutoff 
point for abnormal IMT, and more research is needed to 
further standardize a protocol. 
Another key question that needs to be resolved is how 
the presence of high risk cIMT findings in a patient affects 
management decisions. When abnormal results are found 
on carotid ultrasound screening, physicians are more likely 
to prescribe aspirin and lipid-lowering medication.36 How-
ever, recent meta-analyses suggested that aspirin may not 
offer benefits for primary prevention of cardiovascular dis-
ease when considering the increase in bleeding risk.37,38 
Therefore, a prospective randomized study to determine 
whether the addition of antiplatelet agents, based on the 
presence of high risk cIMT finding alone, may have signifi-
cant benefit needs to be performed. Also, while several clini-
cal trials reported that statin reduced the progression of ca-
rotid atherosclerosis and cardiovascular disease risk, there 
are no prospective studies to show the cardiovascular bene-
fit of prescribing statin based on the presence of high risk 
cIMT. Although the ESC/EAS guidelines for the manage-
ment of dyslipidemia grouped subjects with carotid plaque 
fication in all spectrums of risk categories. Among 10-year 
follow-up results from the CAPS, which included a cohort of 
relatively young and low risk subjects (n=4904) in a primary 
healthcare setting, cIMT did not improve the risk classifica-
tion of individuals.29 Likewise, a recent meta-analysis of 14 
population cohorts of 45828 subjects by Den Ruijter, et al. 
demonstrated that addition of common cIMT to FRS was as-
sociated with a small improvement in 10-year risk predic-
tion of first time myocardial infarction or stroke, but with-
out significant improvement in the net reclassification (0.8%, 
95% CI: 0.1-1.6%). However, the net reclassification im-
provement was 3.6% (95% CI: 2.7-4.6%) in subjects with 
intermediate risk of cardiovascular disease.30 Therefore, 
cIMT may be useful for risk stratification in subjects with 
intermediate risk of cardiovascular disease as determined 
by traditional risk factors. 
 
MEASUREMENT OF cIMT: IS THE 
PROGRESSION OF cIMT A PREDICTOR 
OF CARDIOVASCULAR DISEASE?
With cIMT being accepted as a measure of subclinical ath-
erosclerosis and organ damage, it has been presumed that 
the progression of cIMT, as a marker of atherosclerosis pro-
gression, will be associated with adverse cardiovascular 
prognosis. However, recent publications are contradictory 
to these assumptions. Analysis of the European Lacidipine 
Study on Atherosclerosis showed that both baseline IMT 
and on-treatment IMT, but not treatment induced changes, 
were associated with incident cardiovascular events in treat-
ed hypertensive patients.31 In the PROG-IMT collaborative 
project, a meta-analysis was done on 16 studies with 36984 
participants who had at least two measurements of cIMT 
and outcome data regarding myocardial infarction, stroke, 
and death.32 The results showed that for mean cIMT pro-
gression the hazard ratio was not significantly increased 
(hazard ratio=0.98, 95% CI: 0.95-1.01) when adjusted for 
age, gender, mean cIMT, and vascular risk factors. As such, 
recent European Society of Hypertension (ESH) and Euro-
pean Society of Cardiology (ESC) guidelines did not en-
dorse the usefulness of follow-up cIMT for assessing vas-
cular organ damage in hypertensive subjects.17 From the 
evidence available at this time, it is uncertain as to whether 
or not change in cIMT during the follow-up carotid ultra-
sound is associated with increased risk of cardiovascular 
disease. As such, follow-up carotid ultrasound should not 
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the European Society of Cardiology (ESC). Eur Heart J 2013;34: 
2159-219.
18. Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio 
GA, et al. Prevalence and determinants of carotid atherosclerosis 
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medial thickness is related to cardiovascular risk factors measured 
from childhood through middle age: The Muscatine Study. Circu-
lation 2001;104:2815-9.
20. Pauletto P, Palatini P, Da Ros S, Pagliara V, Santipolo N, Baccill-
ieri S, et al. Factors underlying the increase in carotid intima-me-
dia thickness in borderline hypertensives. Arterioscler Thromb 
Vasc Biol 1999;19:1231-7.
21. Johnson HM, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li 
S, et al. Predictors of carotid intima-media thickness progression 
in young adults: the Bogalusa Heart Study. Stroke 2007;38:900-5.
22. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, et al. 
Prevalence and progression of subclinical atherosclerosis in young-
er adults with low short-term but high lifetime estimated risk for 
cardiovascular disease: the coronary artery risk development in 
young adults study and multi-ethnic study of atherosclerosis. Cir-
culation 2009;119:382-9. 
23. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Predic-
tion of clinical cardiovascular events with carotid intima-media 
thickness: a systematic review and meta-analysis. Circulation 2007; 
115:459-67. 
24. Salonen JT, Salonen R. Ultrasonographically assessed carotid 
as very high risk and recommended an LDL-cholesterol 
treatment goal of 70 mg/dL in these patients, this is based 
more on expert recommendation rather than clinical evi-
dence.39 As such, prospective randomized study to deter-
mine the LDL-cholesterol treatment goal for obtaining 
maximal efficacy in subjects whose risk classification has 
changed according to cIMT needs to be performed. In con-
clusion, although there are still unresolved issues regarding 
the usefulness of cIMT in primary prevention, cIMT is con-
sidered to have additive value in cardiovascular risk predic-
tion, especially in subjects with intermediate risk of cardio-
vascular disease by traditional risk factors. However, 
further studies are needed to determine treatment strategies 
to possibly reduce cardiovascular risk in patients with high 
risk cIMT. 
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